Barely Significant
← all excerpts

State of the art in treatment of small cell lung cancer.

Ther Adv Med Oncol · 2025 · PMC12437200 · PMID 40964483

Europe PMCDOI
1
hedged sentence
0.0164
closest p · 0.3× alpha
0.0164
boldest claim

The sentences

did not reach statistical significancep = 0.0164actually significant
The PD-1 inhibitor, pembrolizumab, combined with platinum/etoposide numerically improved mOS compared to platinum/etoposide alone in the phase III KEYNOTE-604 trial, but this did not reach statistical significance (10.8 vs 9.7 months, p = 0.0164). 37 , 38 Ipilimumab was investigated in a phase II trial with platinum/etoposide first-line but did not improve mOS compared to platinum/etoposide alone. 39 The TIGIT inhibitor, tiragolumab, was investigated in the SKYSCRAPER-02 phase II trial in combination with carboplatin/etoposide but did not produce an improvement in mPFS or mOS. 40 Additionally, ICIs have been investigated as a maintenance-only therapy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.